Arkolith/Insider Trading/PSTX/Form 4

Mylet Johanna

Chief Financial OfficerPoseida Therapeutics, Inc. (PSTX) · full profile →Form 4 · filed Jan 8, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
1 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 8, 2025Tender(U)255K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 8, 2025Disposed to issuer(D)65K—$00
Jan 8, 2025Disposed to issuer(D)73K—$00
Jan 8, 2025Disposed to issuer(D)125K—$00
Jan 8, 2025Disposed to issuer(D)112K—$00
Jan 8, 2025Disposed to issuer(D)82K—$00
Jan 8, 2025Disposed to issuer(D)80K—$00
Jan 8, 2025Disposed to issuer(D)4K—$00
Jan 8, 2025Disposed to issuer(D)35K—$00

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-001084) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML